FDA 블랙박스 경고: ZIPRASIDONE HYDROCHLORIDE
FDA 블랙박스 경고 — ZIPRASIDONE HYDROCHLORIDE (Ziprasidone Hydrochloride)
2026-03-11
블랙박스 경고
Ziprasidone Hydrochloride (ZIPRASIDONE HYDROCHLORIDE) — Bryant Ranch Prepack
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone hydrochloride is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone capsules are not approved for the treatment of patients with dementia-related psychosis ( 5.1 )
약물 상호작용
7 DRUG INTERACTIONS Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated: • Ziprasidone should not be used in combination with other dr
주의사항
이 정보는 FDA 공공 데이터를 기반으로 하며, 의사/약사의 전문적 판단을 대체하지 않습니다.
복용 중인 약이 해당되는지 확인하세요
상호작용 체크하러 가기이 정보는 공식 안전 정보를 기반으로 하며, 의사/약사의 전문적 판단을 대체하지 않습니다.